摘要
Background. Hyperhidrosis (excessive, uncontrollable sweating) can be embarras sing and disabling, significantly impacting social and professional performance and quality of life. Treatments aim to reduce sweating, but few are effective, o ften carrying the risk of significant side-effects. The aims of this study were to evaluate the efficacy and safety of botulinum toxin type A (BTX-A) for plan tar hyperhidrosis and to investigate the role of the Dermojet as a potential inj ection technique. Methods. Ten adult patients (five men, five women), aged 19-5 1 years, with severe, previously unresponsive, plantar hyperhidrosis, were recru ited to this single-center, open-label, noncomparative study.The hyperhidrotic areaof each foot was injected over 15-20 sites without analgesia with 50 U BTX -A +5 mL sterile saline using a Dermojet. Patients were followed up for 8 mont hs with monthly sweat reduction assessments using Minor’s iodine-starch test. Patients provided a treatment self-assessment after completion of follow-up. R esults. Within 7 days post-treatment, eight patients reported significantly dec reased sweating, and seven patients were symptom free for up to 5 months. Patien t self-assessment showed that seven of the 10 patients were satisfied with thei r treatment. One minor adverse event was reported comprising a temporary localiz ed hematoma (one patient). Conclusions. Intracutaneous BTX-A injection using th e Dermojet offers a simple, safe, and effective alternative for treatment of pla ntar hyperhidrosis.
Background. Hyperhidrosis (excessive, uncontrollable sweating) can be embarras sing and disabling, significantly impacting social and professional performance and quality of life. Treatments aim to reduce sweating, but few are effective, o ften carrying the risk of significant side-effects. The aims of this study were to evaluate the efficacy and safety of botulinum toxin type A (BTX-A) for plan tar hyperhidrosis and to investigate the role of the Dermojet as a potential inj ection technique. Methods. Ten adult patients (five men, five women), aged 19-5 1 years, with severe, previously unresponsive, plantar hyperhidrosis, were recru ited to this single-center, open-label, noncomparative study.The hyperhidrotic areaof each foot was injected over 15-20 sites without analgesia with 50 U BTX -A +5 mL sterile saline using a Dermojet. Patients were followed up for 8 mont hs with monthly sweat reduction assessments using Minor's iodine-starch test. Patients provided a treatment self-assessment after completion of follow-up. R esults. Within 7 days post-treatment, eight patients reported significantly dec reased sweating, and seven patients were symptom free for up to 5 months. Patien t self-assessment showed that seven of the 10 patients were satisfied with thei r treatment. One minor adverse event was reported comprising a temporary localiz ed hematoma (one patient). Conclusions. Intracutaneous BTX-A injection using th e Dermojet offers a simple, safe, and effective alternative for treatment of pla ntar hyperhidrosis.
